COMPANY

Exxel Pharma

In addition to EX937, Exxel Pharma is advancing a second program focused on global FAAH inhibitors and targeting Social Anxiety and Autism Spectrum Disorder. From company website Source · Oct 13, 2026

Keywords: EX937

Profile checked Oct 10, 2026

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2024-12-02 Raise Private raise (SEC Form D): $600K sold; issuer “Exxel Pharma, INC.”. Verified from the SEC filing. SEC filing ↗